Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3457263 add-on therapy in type 2 diabetes inadequately controlled on semaglutide or tirzepatide
2024-520328-27-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Modality
- Peptides
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing LY3457263 (Nisotirotide) add-on with Placebo add-on (2 arms). Primary endpoint: Change from baseline in HbA1c at Week 24. Planned start Aug 2025; status: authorised.
02
Drugs
nisotirotide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-520328-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520328-27-00.